[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

AR021746A1 - Procedimiento de fabricacion de particulas recubiertas de gabapentina o de pregabalina. - Google Patents

Procedimiento de fabricacion de particulas recubiertas de gabapentina o de pregabalina.

Info

Publication number
AR021746A1
AR021746A1 ARP990103853A ARP990103853A AR021746A1 AR 021746 A1 AR021746 A1 AR 021746A1 AR P990103853 A ARP990103853 A AR P990103853A AR P990103853 A ARP990103853 A AR P990103853A AR 021746 A1 AR021746 A1 AR 021746A1
Authority
AR
Argentina
Prior art keywords
particles
gabapentine
pregabaline
manufacturing procedure
aminobutyric acid
Prior art date
Application number
ARP990103853A
Other languages
English (en)
Original Assignee
Prographarm Lab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Prographarm Lab filed Critical Prographarm Lab
Publication of AR021746A1 publication Critical patent/AR021746A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5026—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A61K9/2081—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets with microcapsules or coated microparticles according to A61K9/50
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pain & Pain Management (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Rheumatology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Procedimiento para la fabricacion de partículas de análogo del ácido gama aminobutírico recubiertas, cuyo contenido en lactama en peso, con relacion alpeso de análogo del ácido gama-aminobutírico, es inferior al 0,5%, que se caracteriza por pulverizar sobre dichas partículas de análogo del ácido gama-aminobutírico una solucion de recubrimiento que contenga al menos un polímero en un disolvente orgánico. Particulas que pueden obtenerse con dichoprocedimiento y comprimido multiparticulas de administracion oral.
ARP990103853A 1998-08-03 1999-08-03 Procedimiento de fabricacion de particulas recubiertas de gabapentina o de pregabalina. AR021746A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR9810091A FR2781793B1 (fr) 1998-08-03 1998-08-03 Procede de fabrication de granules de gabapentine enrobes

Publications (1)

Publication Number Publication Date
AR021746A1 true AR021746A1 (es) 2002-08-07

Family

ID=9529443

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP990103853A AR021746A1 (es) 1998-08-03 1999-08-03 Procedimiento de fabricacion de particulas recubiertas de gabapentina o de pregabalina.

Country Status (12)

Country Link
US (1) US6488964B2 (es)
EP (1) EP1100467A1 (es)
JP (1) JP2002522375A (es)
CN (1) CN1321083A (es)
AR (1) AR021746A1 (es)
AU (1) AU742701B2 (es)
CA (1) CA2338173A1 (es)
FR (1) FR2781793B1 (es)
NZ (1) NZ509980A (es)
PE (1) PE20001030A1 (es)
WO (1) WO2000007568A1 (es)
ZA (1) ZA200100943B (es)

Families Citing this family (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6539213B1 (en) * 1999-06-14 2003-03-25 Time Domain Corporation System and method for impulse radio power control
US6294198B1 (en) * 1999-08-24 2001-09-25 Purepac Pharmaceutical Co. Pharmaceutical tablet formulation containing gabapentin with improved physical and chemical characteristics and method of making the same
EP1430893A1 (en) * 2000-06-16 2004-06-23 Teva Pharmaceutical Industries Ltd. Stable gabapentin containing more than 20 ppm of chloride ion
EP1384473A1 (en) * 2000-06-16 2004-01-28 Teva Pharmaceutical Industries Ltd. Stable gabapentin containing more than 20 ppm of chlorine ion
PL363155A1 (en) * 2000-06-16 2004-11-15 Teva Pharmaceutical Industries, Ltd. Stable gabapentin having ph within a controlled range
ES2193008T3 (es) 2000-06-16 2004-07-01 Teva Pharmaceutical Industries Ltd. Gabapentina estable que contiene mas de 20 ppm de iones de cloro.
US7056951B2 (en) * 2000-09-26 2006-06-06 Mutual Pharmaceutical Co., Inc. Stable solid dosage forms of amino acids and processes for producing same
US7022678B2 (en) * 2001-03-30 2006-04-04 Warner-Lambert Company Pregabalin lactose conjugates
US20060159743A1 (en) * 2001-10-25 2006-07-20 Depomed, Inc. Methods of treating non-nociceptive pain states with gastric retentive gabapentin
US7612112B2 (en) 2001-10-25 2009-11-03 Depomed, Inc. Methods of treatment using a gastric retained gabapentin dosage
US20070184104A1 (en) * 2001-10-25 2007-08-09 Depomed, Inc. Gastric retentive gabapentin dosage forms and methods for using same
TWI312285B (en) 2001-10-25 2009-07-21 Depomed Inc Methods of treatment using a gastric retained gabapentin dosage
CN1668284A (zh) * 2002-06-07 2005-09-14 兰贝克赛实验室有限公司 加巴喷丁的缓释口服剂型
FR2851734B1 (fr) * 2003-02-28 2006-06-09 Galenix Innovations Procede pour la fabrication d'une composition pharmaceutique sous la forme de comprimes contenant un fibrate et comprimes obtenus selon le procede
AU2004234176B2 (en) 2003-05-02 2010-05-13 Globopharm Pharmazeutische Produktions- Und Handelsgesellschaft M.B.H. Solid pharmaceutical preparation containing levothyroxine and/or liothyronine salts
WO2005046566A2 (en) * 2003-08-04 2005-05-26 Sun Pharmaceutical Industries Limited Stable gabapentin containing composition
CN1867326A (zh) * 2003-09-03 2006-11-22 兰贝克赛实验室有限公司 加巴喷丁的缓释口服片剂及其制备方法
ITMI20032399A1 (it) * 2003-12-09 2005-06-10 Zambon Spa Composizione farmaceutica contenente gabapentina.
AR062647A1 (es) * 2005-01-21 2008-11-26 Pharmanova Inc Formulaciones farmaceutica y metodos de uso
US7417165B2 (en) * 2005-04-06 2008-08-26 Teva Pharmaceutical Industries Ltd. Crystalline forms of pregabalin
US20070066846A1 (en) * 2005-04-11 2007-03-22 Asher Maymon Process for making (S)-Pregabalin
US7488846B2 (en) * 2005-04-11 2009-02-10 Teva Pharmaceuical Industries Ltd. Pregabalin free of lactam and a process for preparation thereof
BRPI0605833A (pt) * 2005-05-10 2007-12-18 Teva Pharma pregabalina livre de ácido isobutilglutárico e um processo para sua preparação
MX2007000524A (es) * 2005-05-10 2007-03-28 Teva Pharma Metodo para la preparacion de pregabalina y sales de ella.
WO2006121557A1 (en) * 2005-05-10 2006-11-16 Teva Pharmaceutical Industries Ltd. Pregabalin free of lactam and a process for preparation thereof
ATE523484T1 (de) * 2005-05-10 2011-09-15 Teva Pharma Optische lösung a us 3-carbamoylmethyl-5-methyl- hexansäure
WO2007035789A1 (en) * 2005-09-19 2007-03-29 Teva Pharmaceutical Industries Ltd. Chiral 3-carbamoylmethyl-5-methyl hexanoic acids, key intermediates for the new synthesis of (s)-pregabalin
US20090176882A1 (en) * 2008-12-09 2009-07-09 Depomed, Inc. Gastric retentive gabapentin dosage forms and methods for using same
EP2019817A2 (en) * 2006-05-24 2009-02-04 Teva Pharmaceutical Industries Ltd. Processes for the preparation of r-(+)-3-(carbamoyl methyl)-5-methylhexanoic acid and salts thereof
EP2071032A3 (en) * 2006-05-31 2009-07-08 Teva Pharmaceutical Industries Ltd The use of enzymatic resolution for the preparation of intermediates of pregabalin
US20080015385A1 (en) * 2006-05-31 2008-01-17 Lilach Hedvati Preparation of (S)-pregabalin-nitrile
GB0616794D0 (en) * 2006-08-24 2006-10-04 Arrow Int Ltd Solid dosage form
BRPI0803092A2 (pt) * 2007-03-22 2011-08-30 Teva Pharma sìntese de (s)-(+)-3-(aminometil)-5-metil ácido hexanóico, (s)-pregabalina
WO2008118369A2 (en) 2007-03-22 2008-10-02 Dendreon Corporation Methods for inducing a natural killer (nk) cell-mediated immune response and for increasing nk cell activity
US20090137842A1 (en) * 2007-10-03 2009-05-28 Vollerner Yuri Pregabalin -4-eliminate, pregabalin 5-eliminate, their use as reference marker and standard, and method to produce pregabalin containing low levels thereof
US8454993B2 (en) * 2007-11-23 2013-06-04 Lupin Limited Controlled release pharmaceutical compositions of pregabalin
SG157299A1 (en) 2008-05-09 2009-12-29 Agency Science Tech & Res Diagnosis and treatment of kawasaki disease
EP2297090A1 (en) * 2008-06-23 2011-03-23 Teva Pharmaceutical Industries Ltd. Stereoselective enzymatic synthesis of (s) or (r)-iso-butyl-glutaric ester
WO2010150221A1 (en) 2009-06-25 2010-12-29 Wockhardt Research Centre Taste masked pharmaceutical compositions of pregabalin
TR200909613A1 (tr) * 2009-12-22 2011-07-21 Sanovel İlaç San. Ve Ti̇c. A.Ş. Pregabalinin farmasötik bileşimleri.
HU230031B1 (hu) 2010-03-01 2015-05-28 Egis Gyógyszergyár Nyilvánosan Működő Részvénytársaság Pregabalint és izomaltot tartalmazó stabilizált gyógyszerkészítmény
WO2013100873A1 (en) * 2011-12-19 2013-07-04 Mahmut Bilgic Pharmaceutical formulation of pregabalin (particle size 300-2500 micrometer)
KR102221846B1 (ko) * 2014-04-07 2021-02-26 영진약품 주식회사 안정성이 개선된 프레가발린을 함유하는 약제학적 조성물 및 이의 제조방법
JP6919119B2 (ja) * 2017-01-23 2021-08-18 日新製薬株式会社 ３位が置換されたγ−アミノ酪酸誘導体を含有する圧縮固形医薬組成物。
FI3760190T3 (fi) 2019-07-03 2023-08-09 Alvogen Inc Pregabaliinin säädellysti vapauttavia tabletteja, sen valmistusmenetelmä ja käyttömenetelmä
CN112843015A (zh) * 2021-04-08 2021-05-28 海南鑫开源医药科技有限公司 一种加巴喷丁胶囊制剂及其制备方法
GB2625579A (en) * 2022-12-21 2024-06-26 Novumgen Ltd An orally disintegrating tablet containing gabapentin or pharmaceutically acceptable salts thereof and the process of preparing the same

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2460891C2 (de) 1974-12-21 1982-09-23 Gödecke AG, 1000 Berlin 1-Aminomethyl-1-cycloalkanessigsäuren und deren Ester, Verfahren zu deren Herstellung und diese Verbindungen enthaltende Arzneimittel
CH658188A5 (de) * 1984-03-23 1986-10-31 Ciba Geigy Ag Lagerstabile schnellzerfallende pharmazeutische presslinge.
SE457326B (sv) * 1986-02-14 1988-12-19 Lejus Medical Ab Foerfarande foer framstaellning av en snabbt soenderfallande kaerna innehaallande bl a mikrokristallin cellulosa
JPS63188621A (ja) * 1987-01-30 1988-08-04 Taisho Pharmaceut Co Ltd 矯味経口製剤
EP0458751A1 (en) * 1990-05-25 1991-11-27 Warner-Lambert Company Delivery system for cyclic amino acids with improved taste, texture and compressibility
CA2068402C (en) * 1991-06-14 1998-09-22 Michael R. Hoy Taste mask coatings for preparation of chewable pharmaceutical tablets
US5464632C1 (en) * 1991-07-22 2001-02-20 Prographarm Lab Rapidly disintegratable multiparticular tablet
FR2679451B1 (fr) * 1991-07-22 1994-09-09 Prographarm Laboratoires Comprime multiparticulaire a delitement rapide.
JPH0710747A (ja) * 1993-04-28 1995-01-13 Takeda Chem Ind Ltd 固形製剤およびその製造方法
DK0804182T3 (da) * 1994-07-27 2002-09-09 Warner Lambert Co Anvendelse af gabapentin ved behandling af angst og panik

Also Published As

Publication number Publication date
FR2781793A1 (fr) 2000-02-04
PE20001030A1 (es) 2000-10-12
JP2002522375A (ja) 2002-07-23
AU4916099A (en) 2000-02-28
FR2781793B1 (fr) 2001-07-20
CA2338173A1 (fr) 2000-02-17
US6488964B2 (en) 2002-12-03
WO2000007568A1 (fr) 2000-02-17
NZ509980A (en) 2003-07-25
AU742701B2 (en) 2002-01-10
ZA200100943B (en) 2001-09-05
US20020012679A1 (en) 2002-01-31
CN1321083A (zh) 2001-11-07
EP1100467A1 (fr) 2001-05-23

Similar Documents

Publication Publication Date Title
AR021746A1 (es) Procedimiento de fabricacion de particulas recubiertas de gabapentina o de pregabalina.
DE3779189D1 (de) Arzneimittel mit komplexierender wirkung auf gallensaeuren, die cholestyramin als wirkstoff enthalten, sowie verfahren zu deren herstellung.
ES2189803T3 (es) Procedimiento.
ATE544447T1 (de) Arzneistoffcoating mit hohem wirkstoffanteil sowie methoden zu dessen herstellung
AR029546A1 (es) Particulas farmaceuticas con sabor enmascarado
FI896109A0 (fi) Kosmetisk eller farmaceutisk sammansaettning som innehaoller mikrosfaerer av polymerer eller feta substanser fyllda med aotminstone en aktiv produkt.
DK0497158T3 (da) Farmaceutisk tyggegummi med acetylsalicylsyre
HUP9904174A2 (hu) Bőrön át történő adagoláshoz szánt gyógyszerkészítmények
MX9707392A (es) Particulas a base de poliaminoacido(s) para utilizarse como vectores de principio(s) activo(s), y metodos para su preparacion.
ES2052182T3 (es) Produccion de comestible revestido con sorbitol.
DE58906926D1 (de) Neue Arzneimittelformulierung sowie Verfahren zu deren Herstellung.
ATE334663T1 (de) Arzneimittelzusammensetzung mit verzögerter wirkstoffabgabe
ATE272331T1 (de) Stabile, durch sprühtrocknung in einen kohlenhydratsubstrat hergestellte zubereitung und verfahren zu deren herstellung
DE69220317D1 (de) Mikropartikeln-Zusammenfassung zur verlängerten Freigabe und Herstellung derselbe
ATE66142T1 (de) Darreichungs- und dosierungsform fuer arzneimittelwirkstoffe, reagentien oder dergleichen sowie verfahren zu deren herstellung.
ATE117203T1 (de) Präparat mit verzögerter freisetzung sowie dessen herstellung.
ES2079943T3 (es) Composiciones acuosas en aerosol para la pulverizacion del cabello que tienen un contenido relativamente bajo en compuestos organicos volatiles.
EP0983995A3 (de) Dimethyl-(3-aryl-but-3-enyl)-aminverbindungen als pharmazeutische Wirkstoffe
EP0382066A3 (de) Verwendung von Dihydroliponsäure als Analgetikum, Antiphlogistikum und/oder Zytoprotektivum
ATE65397T1 (de) Pharmazeutische zusammensetzungen mit gehalt an einem derivat der 3-hydroxy-buttersaeure, ausgewaehlt aus den oligomeren dieser saeure und den estern dieser saeure oder dieser oligomere mit dem 1,3-butan-diol.
ATE95070T1 (de) Pharmazeutische zusammensetzung mit gehalt an einer mischung von kollagen und einem antiseptischen und/oder entzuendungshemmenden wirkstoff und verfahren zu ihrer herstellung.
ATE94410T1 (de) Verfahren zur herstellung einer festen form mit beibehaltender freisetzung aus einer funktionellen aktiven komposition und die bei dem verfahren erhaltene dosierungsform.
ES2062292T3 (es) Un proceso para la preparacion del compuesto que tiene la estructura (7alfa,17alfa)-17-hidroxi-7-metil-19-nor-17-pregn-5(10)-in-3-ona.
HRP20010684B1 (hr) Izravno stlaciva matrica za kontrolirano otpustanje jednostruke dnevne doze klaritromicina
BR9916304A (pt) Goma de mascar contendo agentes ativos demedicamentos